Rinvoq pricing?

Rinvoq (upadacitinib) is one of the newer Janus‑kinase (JAK) inhibitors used mainly for rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and atopic dermatitis. Because it’s a biologic‑like small‑molecule drug, it’s priced at the high end of the market. Below is a quick snapshot of what you’re likely to see on the pharmacy bill in the United States. (Prices can differ in other countries, so let me know if you need international numbers.)

How the numbers break down

1. List price vs. what you pay
   The 8‑10 k/month figure is the manufacturer’s list price. Most commercial insurers negotiate a lower “net price,” which is why patients often see a co‑pay that’s only a few hundred dollars a month.

2. Insurance rules
   Rinvoq usually sits on the “high‑cost tier” of a formulary. Most plans require prior authorization or step‑in therapy before they’ll cover it. After those hurdles are cleared, the remaining cost is what you’ll see in your pharmacy bill.

3. Patient‑assistance and discount programs
   If you’re uninsured or under a high‑deductible plan, the manufacturer’s discount card can cut your monthly out‑of‑pocket cost dramatically. Eligibility is based on income, insurance status, and a short application. Many patients report a 70–90 % reduction.

4. Regional variations
   In Canada, Australia, and many European countries the list price is lower, but patient cost‑sharing still follows the same “tiered” structure. For example, the Canadian list price is around CAD $5,000 per month, but the co‑pay can still be several hundred dollars.

Quick tips for navigating the cost

Bottom line:

• List price: ~$8 k–$9.5 k/month.
• Typical patient out‑of‑pocket (commercial plan): ~$200–$400/month.
• Discount programs: Can bring the cost down to <$100/month for qualifying patients.

If you have a specific insurance plan or country in mind, let me know and I can dig into the exact numbers for you!